Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 3/20 | 0.48 |
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2249917 | 1.00 | CTSL (0.50) | CTSLATMTSHRACECTSB | |
| SCHEMBL5765651 | 1.00 | CTSL (0.50) | CTSLATMTSHRACECTSB | |
| SCHEMBL2249922 | 1.00 | CTSL (0.50) | CTSLATMTSHRACECTSB | |
| SCHEMBL5765656 | 1.00 | CTSL (0.50) | CTSLATMTSHRACECTSB | |
| SCHEMBL5743140 | 1.00 | CTSL (0.50) | CTSLATMTSHRACECTSB | |
| SCHEMBL3868893 | 0.93 | CTSS (0.53) | CTSLATMTSHRACECTSB | |
| SCHEMBL8190987 | 0.93 | CTSS (0.53) | CTSLATMTSHRACECTSB | |
| SCHEMBL1908584 | 0.93 | CTSS (0.53) | CTSLATMTSHRACECTSB | |
| SCHEMBL3868892 | 0.93 | CTSS (0.53) | CTSLATMTSHRACECTSB | |
| SCHEMBL15764599 | 0.92 | ATM (0.47) | CTSLATMTSHRACECTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111094238-B | Carbamoyl phenylalaninol analogues and uses thereof | 杰资制药爱尔兰有限公司 | 2023-06-09 | — | — | CN | disclosed |
| WO-2014084471-A1 | NOVEL N-ACETYL-L-LEUCYL-L-LEUCYL-L-NORLEUCINAL (ALLN) DERIVATIVE COMPOUND, COMPOSITION FOR PREVENTING OR TREATING MALARIA, CONTAINING SAME AS ACTIVE INGREDIENT, AND USE THEREOF | 원광대학교 산학협력단 (KR) | 2014-06-05 | — | — | WO | disclosed |
| US-20060223814-A1 | Nk-2 antagonist basic linear compounds and formulations containing them | MENARINI RICERCHE S.P.A. (IT) | 2006-10-05 | — | — | US | disclosed |
| EP-1620432-A1 | NK-2 ANTAGONIST BASIC LINEAR COMPOUNDS AND FORMULATIONS CONTAINING THEM | Menarini Ricerche S.p.A. (IT) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004094412-A1 | NK-2 ANTAGONIST BASIC LINEAR COMPOUNDS AND FORMULATIONS CONTAINING THEM | MENARINI RICERCHE S.P.A. (IT) | 2004-11-04 | — | — | WO | disclosed |
| US-5122610-A | Renin inhibitor intermediates | BAYER AKTIENGESELLSCHAFT (DE) | 1992-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223814-A1 | Nk-2 antagonist basic linear compounds and formulations containing them | BDKRB2, KLK2, BDKRB1 | CTSL 525/4885ATM 2561/4885TSHR 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.